Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences

Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences

NEW YORK, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc.
(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI)
disorders and diseases, announced today that President and CEO Gary S. Jacob,
Ph.D., will be presenting a corporate overview at two healthcare conferences
in New York this month.

  *Citi 2013 Global Healthcare Conference on Monday, February 25th, 2013 at
    10:20am at the Hilton New York Hotel.
  *RBC Capital Markets Healthcare Conference on Tuesday, February 26th, 2013
    at 4:35pm at the New York Palace Hotel.

Live audio webcasts of both presentations will be available under the investor
relations section of Synergy's website at Replays of
the presentations will be available for 60 days afterward.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate, plecanatide, is a synthetic analog of the human
gastrointestinal hormone uroguanylin, and functions by activating the
guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy
completed a positive Phase I study of plecanatide in healthy volunteers, and
positive Phase IIa and Phase IIb/III clinical trials in patients with chronic
idiopathic constipation (CIC).Detailed positive findings from a recently
completed 951 patient CIC clinical trial will be presented at a major
scientific meeting this year.Synergy is also developing plecanatide for the
treatment of irritable bowel syndrome with constipation (IBS-C), having
initiated the first trial in IBS-C patients in late 2012. Synergy's second
GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel
diseases, and has recently completed its first Phase I trial in healthy
volunteers. More information is available at

CONTACT: Media Contact: Janet Skidmore
         Office:  215-658-4915
         Mobile:  215-429-2917
         Investor Contact: Danielle Spangler
         The Trout Group
         (646) 378-2924
Press spacebar to pause and continue. Press esc to stop.